Reports

Each year, Lundbeck produces a wide range of financial reports to inform the investment community. You will find them here. 

View all reports

Share information

There are many factors that contribute to the activity of Lundbeck's shares. Here are some documents and background facts that have proven useful to our shareholders and potential investors.

View share information

Subscribe

Keep Updated.
Receive releases by email.

Subscribe
02-Jul-2009
Lu AA24530 shows positive results in major depressive disorder phase II study
H. Lundbeck A/S (Lundbeck) today announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD).
25-Jun-2009
Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia
H. Lundbeck A/S (LUN.CO; LUN DC) announced today that the company has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for Serdolect® (sertindole) for the treatment of schizophrenia.
View all releases

 
Upcoming event
Interim report for 2nd quarter 2009 - 13 August 2009


Investor relations contacts

Jacob Tolstrup
Jacob Tolstrup
Director, IR & Communication
Phone  +45 3643 3079
Fax  +45 3643 8262
jtl@lundbeck.com
Palle Holm Olesen
Palle Holm Olesen
Head of Investor Relations
Phone  +45 3643 2426
Fax  +45 3643 8262
palo@lundbeck.com

Magnus Thorstholm Jensen
Investor Relatiosn Officer
Phone  +45 3643 3816
Fax  +45 3643 8262
matj@lundbeck.com
H. Lundbeck A/S
Ottiliavej 9
DK-2500 Copenhagen Valby
Phone +45 3630 1311
Fax +45 3630 1940
information@lundbeck.com
The specialist in psychiatry and pioneer in neurology
Disclaimer